Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 75

Sort by

Sort Order Select

Journal Articles

Timed inhibition of the sting pathway improves tissue regeneration and prevents GVHD following allo-HSCT

Sascha Göttert, Chiara Suriano, Omer Khalid, Paul Heinrich, Sakhila Ghimire, Eva Vonbrunn, Elisabeth Meedt, Petra Hoffmann, Matthias Edinger, Daniela Weber, Daniel Wolff, Michael Rehli, Maike Büttner-Herold, Wolfgang Herr, Ernst Holler, Christian Schmidl, Hendrik Poeck

Blood (2025) 146 (Supplement 1): 2317.

https://doi.org/10.1182/blood-2025-2317

Published: 2025

Journal Articles

Propensity score matching analysis comparing the efficacy and treatment outcomes of belumosudil treatment with ruxolitinib therapy as second-line or beyond in chronic GVHD patients after steroid failure

Sergio Rodriguez-Rodriguez, Rebeca Bailen, Keven Vachon, Brittany Salter, Christopher Lemieux, Kareem Jamani, Mohamed Elemary, Sylvie Lachance, Jonas Mattsson, Kylie Lepic, Amani Ahmed, Jennifer White, Felipe Peña-Muñoz, Juan Alberto Martín González, Jose Antonio Perez Simon, Matthias Fante, Daniel Wolff, Mi Kwon, Dennis Kim

Blood (2025) 146 (Supplement 1): 6031.

https://doi.org/10.1182/blood-2025-6031

Published: 2025

Journal Articles

Propensity score matching analysis comparing the efficacy and long-term outcomes of belumosudil to the best available treatment as a historical control, used as second-line therapy or beyond for chronic GVHD after steroid failure.

Blood (2025) 146 (Supplement 1): 6025.

https://doi.org/10.1182/blood-2025-6025

Published: 2025

Journal Articles

TFH subsets in patients after allogenic transplant are dysregulated prior to chronic GVHD development

Isabel Sandner, Katharina Habenicht, Thomas Winkler, Petra Hoffmann, Friederike Berberich-Siebelt, Daniel Wolff, Julia Winkler, Andreas Mackensen, Silvia Spoerl

Blood (2025) 146 (Supplement 1): 6023.

https://doi.org/10.1182/blood-2025-6023

Published: 2025

Journal Articles

Peripheral plasmablast expansion as a predictor and therapeutic target in chronic GVHD

Katharina Habenicht, Jana Wanzek, Anna Bootz, Simon Schäfer, Andreas Hiergeist, Matthias Fante, Andrea Schneider, Ingrid Vasova, Michael Rehli, Petra Hoffmann, Stefan Wirtz, André Gessner, Julia Winkler, Daniel Wolff, Thomas Winkler

Blood (2025) 146 (Supplement 1): 4245.

https://doi.org/10.1182/blood-2025-4245

Published: 2025

Journal Articles

Multicenter real-world experience of belumosudil treatment in heavily pretreated patients with steroid-refractory chronic graft-versus-host disease: Clinical outcomes and risk factor analysis for failure-free survival.

Blood (2025) 146 (Supplement 1): 4239.

https://doi.org/10.1182/blood-2025-4239

Published: 2025

Journal Articles

The role of microbial metabolites in fecal microbiota transplantation in patients with acute gvhd of the gut

Blood (2025) 146 (Supplement 1): 4236.

https://doi.org/10.1182/blood-2025-4236

Published: 2025

Journal Articles

Efficacy and safety of the ROCK2-inhibitor belumosudil for chronic gvhd treatment: Multicenter retrospective analysis of a large german-austrian cohort of the belumosudil managed-access program.

Blood (2025) 146 (Supplement 1): 6011.

https://doi.org/10.1182/blood-2025-6011

Published: 2025

Journal Articles

Long-term treatment duration and safety of axatilimab among patients with chronic graft-versus-host disease in AGAVE-201

Carrie Kitko, Amandeep Salhotra, Mi Kwon, Zhenyi Xue, Valkal Bhatt, John Galvin, Patrick Hardesty, Silvia Mosher, Daniel Wolff

Blood (2025) 146 (Supplement 1): 6010.

https://doi.org/10.1182/blood-2025-6010

Published: 2025

Journal Articles

Multi-faceted influence of immunomodulatory metabolites on CAR-T cell therapy

Dhyani Shah, Markus Perl, Matthias Fante, Severin Guetter, Simon Holzinger, Luisa-Marie Becker, Misbah Tariq, Philipp Meanauer, Simon Delahais, Gloria Lutzny-Geier, Julian Scherer, Sascha Goettert, Konstantin Herfeld, Paul Heinrich, Klaus-Georg Kreitmeier, Wolfgang Herr, Janina Doerr, Dennis Harrer, Leo Hansmann, Marcel Trefny, Matthias Edinger, Daniel Wolff, Daniela Weber, Elisabeth Meedt, André Gessner, Ernst Holler, Tobias Wertheimer, Klaus Neuhaus, Tingting Zheng, Kai Ziegler-Martin, David M. Cordas Dos Santos, Sebastian Theurich, Melanie Schirmer, Jonas Schluter, Michael Schmitt, Karin Kleigrewe, Markus Feuerer, Christoph Heuser-Loy, Jeremy Baldwin, Michael Hudecek, Luca Gattinoni, Marion Subklewe, Viktoria Blumenberg, Maria-Luisa Schubert, Christoph Stein-Thoeringer, Maik Luu, Sebastian Kobold, Erik Thiele Orberg, Hendrik Poeck

Blood (2025) 146 (Supplement 1): 2343.

https://doi.org/10.1182/blood-2025-2343

Published: 2025

Journal Articles

Distinct Biological Subtypes of Chronic GVHD after Pediatric Hematopoietic Cell Transplantation

Blood blood.2025028625.

https://doi.org/10.1182/blood.2025028625

Published: 2025

Includes: Supplemental data

Journal Articles

Mucosal calprotectin is associated with severity of aGI-GVHD and poor outcomes after allogeneic stem cell transplantation

Blood blood.2025029402.

https://doi.org/10.1182/blood.2025029402

Published: 2025

Includes: Supplemental data

Journal Articles

Expansions of circulating plasmablasts producing commensal-reactive IgA antibodies are predictors for chronic GVHD

Blood (2025) 145 (26): 3178–3188.

https://doi.org/10.1182/blood.2024027301

Published: 2025

Includes: Supplemental data

Journal Articles

Developing Evidence-Based Guidelines for Optimal Patient Communication Prior and Post Allogeneic Stem Cell Transplantation

Anne Herrmann, Helene Schoemans, Eva Wilhelm, Guy Tavori, Nada Hamad, Meredith A. Cowden, Anna Barata, Francis A. Ayuk, Wolfgang Herr, Joerg Halter, Stephanie Lee, Daniel Wolff

Blood (2024) 144 (Supplement 1): 4917.

https://doi.org/10.1182/blood-2024-199052

Published: 2024

Journal Articles

Outcome after Allogeneic Stem Cell Transplant in Adults with Inherited Myeloid Malignancies - a Multicenter Retrospective Analysis on Behalf of the German Cooperative Transplant Study Group

Blood (2024) 144 (Supplement 1): 2179.

https://doi.org/10.1182/blood-2024-204878

Published: 2024

Journal Articles

Changes in Immunosuppressive Treatment of Chronic Graft-Versus-Host Disease: Results from a Survey within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland

Blood (2024) 144 (Supplement 1): 7334.

https://doi.org/10.1182/blood-2024-200375

Published: 2024

Journal Articles

Dynamics of Overall and Organ-Specific Responses to Axatilimab in Chronic Graft-Versus-Host Disease: Analysis from the Agave-201 Study

Hannah Choe, Amandeep Salhotra, Nosha Farhadfar, Mi Kwon, Britnie Thomas, Vedran Radojcic, Chuan Tian, Shuyuan Lou, Daniel Wolff, Stephanie J. Lee

Blood (2024) 144 (Supplement 1): 98.

https://doi.org/10.1182/blood-2024-209965

Published: 2024

Journal Articles

Recovery of the Intestinal Microbiome in Patients at Day +100 after Allogeneic Stem Cell Transplantation Is Defined By Microbial Metabolite Profiles and Linked to Long-Term Outcomes

Blood (2024) 144 (Supplement 1): 780.

https://doi.org/10.1182/blood-2024-199035

Published: 2024

Journal Articles

Immunomodulatory Microbial Metabolites Protect Against Graft-Vs-Host Disease and Enhance Anti-Leukemia Responses in Mice and Patients Receiving Stem Cell Transplantation

Sascha Göttert, Erik Thiele-Orberg, Kaiji Fan, Paul Heinrich, Daniel Wolff, Daniela Weber, Florian Bassermann, Petra Hoffmann, Matthias Edinger, Natalie Koehler, André Gessner, Wolfgang Herr, Simon M Heidegger, Ernst Holler, Hendrik Poeck

Blood (2024) 144 (Supplement 1): 264.

https://doi.org/10.1182/blood-2024-205921

Published: 2024

Journal Articles

Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)

Katja Sockel, Annika Neu, Maren Goeckenjan, Markus Ditschkowski, Inken Hilgendorf, Nicolaus Kröger, Francis A. Ayuk, Friedrich Stoelzel, Jan Moritz Middeke, Matthias Eder, Wolfgang Bethge, Jürgen Finke, Hartmut Bertz, Guido Kobbe, Martin Kaufmann, Uwe Platzbecker, David Beverungen, Christoph Schmid, Malte von Bonin, Katharina Egger-Heidrich, Lisa Heberling, Karolin Trautmann-Grill, Raphael Teipel, Gesine Bug, Johanna Tischer, Alessia Fraccaroli, Matthias Fante, Daniel Wolff, Thomas Luft, Julia Winkler, Kerstin Schäfer-Eckart, Christof Scheid, Udo Holtick, Stefan Klein, Igor Wolfgang Blau, Andreas Burchert, Gerald Wulf, Justin Hasenkamp, Rainer Schwerdtfeger, Stephan Kaun, Christian Junghanss, Friederike Wortmann, Susann Winter, Helga Neidlinger, Catrin Theuser, Jan Beyersmann, Martin Bornhaeuser, Sandra Schmeller, Johannes Schetelig

Blood (2024) 144 (14): 1532–1542.

https://doi.org/10.1182/blood.2024024342

Published: 2024

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Timed inhibition of the sting pathway improves tissue regeneration and prevents GVHD following allo-HSCT

Propensity score matching analysis comparing the efficacy and treatment outcomes of belumosudil treatment with ruxolitinib therapy as second-line or beyond in chronic GVHD patients after steroid failure

Propensity score matching analysis comparing the efficacy and long-term outcomes of belumosudil to the best available treatment as a historical control, used as second-line therapy or beyond for chronic GVHD after steroid failure.

TFH subsets in patients after allogenic transplant are dysregulated prior to chronic GVHD development

Peripheral plasmablast expansion as a predictor and therapeutic target in chronic GVHD

Multicenter real-world experience of belumosudil treatment in heavily pretreated patients with steroid-refractory chronic graft-versus-host disease: Clinical outcomes and risk factor analysis for failure-free survival.

The role of microbial metabolites in fecal microbiota transplantation in patients with acute gvhd of the gut

Efficacy and safety of the ROCK2-inhibitor belumosudil for chronic gvhd treatment: Multicenter retrospective analysis of a large german-austrian cohort of the belumosudil managed-access program.

Long-term treatment duration and safety of axatilimab among patients with chronic graft-versus-host disease in AGAVE-201

Multi-faceted influence of immunomodulatory metabolites on CAR-T cell therapy

Distinct Biological Subtypes of Chronic GVHD after Pediatric Hematopoietic Cell Transplantation

Mucosal calprotectin is associated with severity of aGI-GVHD and poor outcomes after allogeneic stem cell transplantation

Expansions of circulating plasmablasts producing commensal-reactive IgA antibodies are predictors for chronic GVHD

Developing Evidence-Based Guidelines for Optimal Patient Communication Prior and Post Allogeneic Stem Cell Transplantation

Outcome after Allogeneic Stem Cell Transplant in Adults with Inherited Myeloid Malignancies - a Multicenter Retrospective Analysis on Behalf of the German Cooperative Transplant Study Group

Changes in Immunosuppressive Treatment of Chronic Graft-Versus-Host Disease: Results from a Survey within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland

Dynamics of Overall and Organ-Specific Responses to Axatilimab in Chronic Graft-Versus-Host Disease: Analysis from the Agave-201 Study

Recovery of the Intestinal Microbiome in Patients at Day +100 after Allogeneic Stem Cell Transplantation Is Defined By Microbial Metabolite Profiles and Linked to Long-Term Outcomes

Immunomodulatory Microbial Metabolites Protect Against Graft-Vs-Host Disease and Enhance Anti-Leukemia Responses in Mice and Patients Receiving Stem Cell Transplantation

Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only